When most of the companies are diluting their shares and insiders are selling, KemPharm, Inc. (KMPH) does the opposite.
Insiders are buying and the Board of Directors authorizes a program to repurchase up to $50 million of the Company’s outstanding stock valid through December 31, 2023. It is equivalent to 18% of KemPharm’s current market capitalization.
Because...
Target 1: $29
Target 2: $45
Target 3: $80
If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
$KMPH has very weak support and could retrace much lower regions in near completion of a head and shoulders formation. All signs are grossly bearish, including many large-scale sell orders having been placed in the last five days. The bigger investors have pulled the rug-- Target new entries much lower on this position if possible.
Best,
BDR
